• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    2/15/24 8:05:57 AM ET
    $ADPT
    $AMWL
    $APLT
    $FRES
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Real Estate
    Real Estate
    Get the next $ADPT alert in real time by email

    Gainers

    • Applied Therapeutics (NASDAQ:APLT) stock rose 24.6% to $3.34 during Thursday's pre-market session. The company's market cap stands at $257.9 million.
    • Meihua Intl Medical Techs (NASDAQ:MHUA) stock moved upwards by 24.32% to $1.38. The market value of their outstanding shares is at $33.4 million.
    • KalVista Pharma (NASDAQ:KALV) shares moved upwards by 15.83% to $16.68. The company's market cap stands at $576.4 million.
    • Recursion Pharmaceuticals (NASDAQ:RXRX) stock increased by 14.83% to $12.54. The company's market cap stands at $2.7 billion.
    • American Well (NYSE:AMWL) stock rose 11.71% to $1.24. The company's market cap stands at $356.5 million. As per the press release, Q4 earnings came out yesterday.
    • Scorpius Holdings (AMEX:SCPX) shares increased by 11.68% to $0.37. The company's market cap stands at $9.6 million.

    Losers

    • Vivos Therapeutics (NASDAQ:VVOS) shares fell 54.7% to $2.29 during Thursday's pre-market session. The company's market cap stands at $3.0 million.
    • Renalytix (NASDAQ:RNLX) stock decreased by 27.26% to $0.88. The market value of their outstanding shares is at $43.9 million. As per the news, the Q2 earnings report came out yesterday.
    • FibroBiologics, Inc. - Common Stock (NASDAQ:FBLG) shares declined by 20.01% to $12.2.
    • Healthcare Triangle (NASDAQ:HCTI) shares declined by 19.54% to $2.87. The market value of their outstanding shares is at $12.3 million.
    • Adaptive Biotechnologies (NASDAQ:ADPT) stock decreased by 15.86% to $3.32. The company's market cap stands at $479.9 million. As per the press release, Q4 earnings came out yesterday.
    • Fresh2 Group (NASDAQ:FRES) shares fell 15.52% to $0.38. The market value of their outstanding shares is at $9.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADPT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADPT
    $AMWL
    $APLT
    $FRES

    CompanyDatePrice TargetRatingAnalyst
    KalVista Pharmaceuticals Inc.
    $KALV
    1/9/2026$32.00 → $35.00Buy
    Needham
    KalVista Pharmaceuticals Inc.
    $KALV
    1/6/2026$28.00 → $32.00Buy
    Needham
    Recursion Pharmaceuticals Inc.
    $RXRX
    12/17/2025$11.00Neutral → Overweight
    Analyst
    Applied Therapeutics Inc.
    $APLT
    12/12/2025Outperform → Neutral
    Robert W. Baird
    Applied Therapeutics Inc.
    $APLT
    12/3/2025$1.00Outperform → Market Perform
    Leerink Partners
    Adaptive Biotechnologies Corporation
    $ADPT
    12/2/2025$21.00Equal-Weight
    Morgan Stanley
    Adaptive Biotechnologies Corporation
    $ADPT
    9/30/2025$20.00Buy
    Guggenheim
    Recursion Pharmaceuticals Inc.
    $RXRX
    7/3/2025$5.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $ADPT
    $AMWL
    $APLT
    $FRES
    SEC Filings

    View All

    SEC Form S-8 filed by Adaptive Biotechnologies Corporation

    S-8 - Adaptive Biotechnologies Corp (0001478320) (Filer)

    2/27/26 5:05:19 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Healthcare Triangle Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Healthcare Triangle, Inc. (0001839285) (Filer)

    2/27/26 5:00:18 PM ET
    $HCTI
    EDP Services
    Technology

    SEC Form 424B5 filed by Healthcare Triangle Inc.

    424B5 - Healthcare Triangle, Inc. (0001839285) (Filer)

    2/27/26 12:12:02 PM ET
    $HCTI
    EDP Services
    Technology

    $ADPT
    $AMWL
    $APLT
    $FRES
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $235,500 worth of shares (25,000 units at $9.42) (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    4/11/25 5:22:07 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $1,498,661 worth of shares (161,700 units at $9.27) (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    2/14/25 7:45:15 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $967,145 worth of shares (104,489 units at $9.26) (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    2/11/25 7:51:08 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADPT
    $AMWL
    $APLT
    $FRES
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Healthcare Triangle Subsidiary QuantumNexis Inc. Launches its Dubai, UAE Operations to accelerate Digital Health Transformation across the GCC Countries

    The Dubai Operation strengthens Healthcare Triangle's mission to accelerate TeleHelath, Digital Therapeutics and population-scale care delivery across GCC.PLEASANTON, Calif., Feb. 27, 2026 /CNW/ -- Healthcare Triangle, Inc. (NASDAQ:HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions including managed services, cloud enablement, and data analytics for the healthcare and life sciences industries, today announced that its subsidiary QuantumNexis Inc. has launched its Dubai, UAE operations in Meydan Free Zone to deliver clinically validated digital mental health solutions and AI powered Hospital Information System to the GCC markets. "This marks a major strategic expans

    2/27/26 7:18:00 AM ET
    $HCTI
    EDP Services
    Technology

    Healthcare Triangle Announces Approximately $3.959 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

    PLEASANTON, Calif., Feb. 26, 2026 /CNW/ -- Healthcare Triangle, Inc. (NASDAQ:HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions for healthcare and life sciences, today announced today that it has entered into definitive agreements for the purchase and sale of 681,553 shares of common stock (or prefunded warrants in lieu thereof), par value $0.00001 per share, at a purchase price of $5.81 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about February 27, 2026, subject to the satisfaction of customary closing conditions. D. Boral Capital, LLC is acting as sole placement agent fo

    2/26/26 3:26:00 PM ET
    $HCTI
    EDP Services
    Technology

    Healthcare Triangle Subsidiary QuantumNexis and TNG Digital, the Operator of Malaysia's Leading Digital Financial Services and Lifestyle App, Announce Strategic Partnership to Provide Digital Mental Health Solutions to Its Over 25 Million Customers in Malaysia

    The partnership strengthens Healthcare Triangle's leadership at the intersection of digital health, fintech, and population-scale care delivery.PLEASANTON, Calif., Feb. 25, 2026 /CNW/ -- Healthcare Triangle, Inc. (NASDAQ:HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions including managed services, cloud enablement, and data analytics for the healthcare and life sciences industries, today announced that its subsidiary QuantumNexis Malaysia Sdn Bhd (together with QuantumNexis, Inc. are hereafter referred to as "QuantumNexis") has entered a strategic partnership with TNG Digital, Malaysia's largest and most trusted digital payments and financial services platform, to

    2/25/26 4:10:00 PM ET
    $HCTI
    EDP Services
    Technology

    $ADPT
    $AMWL
    $APLT
    $FRES
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF MEDICAL OFFICER Audhya Paul K. converted options into 11,250 shares and sold $83,345 worth of shares (5,354 units at $15.57), increasing direct ownership by 4% to 138,983 units (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    2/24/26 7:44:46 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER Palleiko Benjamin L converted options into 23,250 shares and sold $156,197 worth of shares (10,034 units at $15.57), increasing direct ownership by 3% to 442,883 units (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    2/24/26 7:44:00 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF DEVELOPMENT OFFICER Yea Christopher converted options into 6,875 shares and sold $67,669 worth of shares (4,347 units at $15.57), increasing direct ownership by 1% to 226,701 units (SEC Form 4)

    4 - KalVista Pharmaceuticals, Inc. (0001348911) (Issuer)

    2/24/26 7:43:20 PM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADPT
    $AMWL
    $APLT
    $FRES
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham reiterated coverage on KalVista Pharmaceuticals with a new price target

    Needham reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $35.00 from $32.00 previously

    1/9/26 7:49:25 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham reiterated coverage on KalVista Pharmaceuticals with a new price target

    Needham reiterated coverage of KalVista Pharmaceuticals with a rating of Buy and set a new price target of $32.00 from $28.00 previously

    1/6/26 7:58:35 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Recursion Pharmaceuticals upgraded by Analyst with a new price target

    Analyst upgraded Recursion Pharmaceuticals from Neutral to Overweight and set a new price target of $11.00

    12/17/25 8:47:25 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    $AMWL
    $APLT
    $FRES
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 5, 2021 - Coronavirus (COVID-19) Update: FDA Authorizes Adaptive Biotechnologies T-Detect COVID Test

    For Immediate Release: March 05, 2021 Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the T-Detect COVID Test developed by Adaptive Biotechnologies. The T-Detect COVID Test is a next generation sequencing based (NGS) test to aid in identifying individuals with an adaptive T cell immune response to SARS-CoV-2, indicating recent or prior infection with SARS-CoV-2.  “Today’s authorization further und

    3/5/21 10:37:33 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    $AMWL
    $APLT
    $FRES
    Leadership Updates

    Live Leadership Updates

    View All

    Applied Therapeutics Reports Third Quarter 2025 Financial Results

    –   Update on regulatory strategy for govorestat for the treatment of CMT-SORD following receipt of Type C meeting minutes –   Meeting scheduled with the FDA in 4Q 2025 to discuss govorestat for the treatment of Classic Galactosemia –   New data on govorestat for the treatment of PMM2-CDG published in JIMD and presented at the 2025 ASHG Annual Meeting –   Announces Board of Directors Leadership Transition NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT) (the "Company"), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today reported financial results for the third quarter ended September 30

    11/13/25 7:00:00 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

    Salt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board of Directors has unanimously approved a leadership transition plan to become effective January 1, 2026: Najat Khan, Ph.D., currently Chief R&D and Commercial Officer and a Board Member, will succeed Co-Founder and CEO Chris Gibson, Ph.D., as Chief Executive Officer and President. Najat will also continue in her role as a member of the Board of Directors.  Chris Gibson, Ph. D., current Co-Founder and CEO, will transition to Chairman of the Board of Directors and an interim Executive Adv

    11/5/25 6:28:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced the appointments of Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer, effective October 6, 2025. "I am pleased to welcome Bilal and Linea to our leadership team as we advance the global launch of EKTERLY," said Ben Palleiko, Chief Executive Officer of KalVista. "Their respective expertise in operations and human resources will be instrumental as we deliver on our commitment to people living with HAE." "I am excited to join KalVista and collaborate with such a talented team," said Mr. Arif. "This is a pivotal time for EKTERLY, and I am focused on strengthening the operational framework to ensure pe

    10/6/25 7:00:00 AM ET
    $KALV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADPT
    $AMWL
    $APLT
    $FRES
    Financials

    Live finance-specific insights

    View All

    Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25

    Salt Lake City, UT, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, before the open of the financial markets. Recursion will host a (L)earnings Call on February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion's X, LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/TQ4vgUTLKsFm

    2/18/26 8:30:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amwell® Announces Results for Fourth Quarter and Full Year 2025

    BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today announced financial results for the fourth quarter and full year ended December 31, 2025. The company's fourth quarter and full year 2025 earnings report can be viewed at investors.amwell.com. Amwell will host a conference call to discuss its financial results today at 5 p.m. ET. The call can be accessed via a live audio webcast at https://edge.media-server.com/mmc/p/7o2zjx2o/. A webcast replay will be available for approximately 90 days at investors.amwell.com. About Amwell Amwell offers payers and health systems a si

    2/12/26 4:05:00 PM ET
    $AMWL
    Real Estate

    Amwell® to report fourth quarter and full year 2025 operating results

    BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will report fourth quarter and full year 2025 operating results after stock market trading hours on Thursday, Feb. 12. Following the distribution of the earnings alert via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company's operating results and provide a general business update. The full earnings report and the live audio webcast can be accessed by visiting the Investors section of the company's website. A webcast replay of the call will be available at

    2/5/26 4:05:00 PM ET
    $AMWL
    Real Estate

    $ADPT
    $AMWL
    $APLT
    $FRES
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Meihua International Medical Technologies Co. Ltd.

    SC 13G - Meihua International Medical Technologies Co., Ltd. (0001835615) (Subject)

    11/14/24 6:08:55 PM ET
    $MHUA
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Applied Therapeutics Inc.

    SC 13G/A - Applied Therapeutics, Inc. (0001697532) (Subject)

    11/14/24 5:47:55 PM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Applied Therapeutics Inc.

    SC 13G/A - Applied Therapeutics, Inc. (0001697532) (Subject)

    11/14/24 4:50:26 PM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care